1. Home
  2. IKT vs FEIM Comparison

IKT vs FEIM Comparison

Compare IKT & FEIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IKT
  • FEIM
  • Stock Information
  • Founded
  • IKT 2008
  • FEIM 1961
  • Country
  • IKT United States
  • FEIM United States
  • Employees
  • IKT N/A
  • FEIM N/A
  • Industry
  • IKT Biotechnology: Pharmaceutical Preparations
  • FEIM Electrical Products
  • Sector
  • IKT Health Care
  • FEIM Industrials
  • Exchange
  • IKT Nasdaq
  • FEIM Nasdaq
  • Market Cap
  • IKT 159.2M
  • FEIM 129.3M
  • IPO Year
  • IKT 2020
  • FEIM N/A
  • Fundamental
  • Price
  • IKT $3.05
  • FEIM $19.42
  • Analyst Decision
  • IKT Strong Buy
  • FEIM
  • Analyst Count
  • IKT 2
  • FEIM 0
  • Target Price
  • IKT $6.50
  • FEIM N/A
  • AVG Volume (30 Days)
  • IKT 451.1K
  • FEIM 146.8K
  • Earning Date
  • IKT 11-14-2024
  • FEIM 12-10-2024
  • Dividend Yield
  • IKT N/A
  • FEIM 5.15%
  • EPS Growth
  • IKT N/A
  • FEIM 183.83
  • EPS
  • IKT N/A
  • FEIM 0.82
  • Revenue
  • IKT $1.00
  • FEIM $60,188,000.00
  • Revenue This Year
  • IKT N/A
  • FEIM N/A
  • Revenue Next Year
  • IKT N/A
  • FEIM N/A
  • P/E Ratio
  • IKT N/A
  • FEIM $23.65
  • Revenue Growth
  • IKT N/A
  • FEIM 21.33
  • 52 Week Low
  • IKT $1.12
  • FEIM $8.62
  • 52 Week High
  • IKT $4.20
  • FEIM $20.33
  • Technical
  • Relative Strength Index (RSI)
  • IKT 51.80
  • FEIM 80.90
  • Support Level
  • IKT $2.90
  • FEIM $18.09
  • Resistance Level
  • IKT $4.20
  • FEIM $20.33
  • Average True Range (ATR)
  • IKT 0.41
  • FEIM 1.08
  • MACD
  • IKT -0.07
  • FEIM 0.28
  • Stochastic Oscillator
  • IKT 11.54
  • FEIM 88.07

About IKT Inhibikase Therapeutics Inc.

Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.

About FEIM Frequency Electronics Inc.

Frequency Electronics Inc is engaged in the design, development, and manufacture of high-precision timing, and frequency control products for space, air, sea, and terrestrial applications. The company has FEI-NY and FEI-Zyfer reportable segments. It derives the majority of its revenues from the FEI-NY segment. FEI-NY segment operations consist principally of precision time and frequency control products used in three principal markets namely communication satellites (both commercial and U.S. Government-funded); terrestrial cellular telephone or other ground-based telecommunication stations; and other components and systems for the U.S. military.

Share on Social Networks: